NewAmsterdam Pharma (NAMS) Cash & Equivalents (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Cash & Equivalents data on file, last reported at $457.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 38.86% year-over-year to $457.6 million; the trailing twelve-month figure through Mar 2026 stood at $457.6 million (down 38.86% YoY), and the FY2025 full-year result was $490.0 million, down 36.51% from the prior year.
• Cash & Equivalents retreated to $457.6 million in Q1 2026, from $490.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $771.7 million in Q4 2024 to a low of $340.4 million in Q4 2023.
• A 5-year average of $494.2 million and a median of $452.5 million in 2026 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 636.6% in 2022 and sank 38.86% in 2026, its largest moves.
• Tracing NAMS's Cash & Equivalents over 5 years: stood at $447.4 million in 2022, then slipped by 23.9% to $340.4 million in 2023, then jumped by 126.68% to $771.7 million in 2024, then plunged by 36.51% to $490.0 million in 2025, then declined by 6.61% to $457.6 million in 2026.
• Business Quant data shows NAMS's Cash & Equivalents at $457.6 million in Q1 2026, $490.0 million in Q4 2025, and $538.4 million in Q3 2025.